加载中
Lantern Pharma Inc. is a clinical-stage biotechnology firm dedicated to revolutionizing drug development through the strategic application of artificial intelligence, machine learning, and comprehensive genomic data analysis. Their primary drug candidate, LP-100, is currently undergoing Phase II clinical trials, targeting metastatic, castration-resistant prostate cancer. The company is also advancing LP-300 as a potential combination therapy for non-small cell lung cancer adenocarcinoma, specifically in individuals who are non-smokers or have never smoked. Furthermore, their preclinical pipeline includes LP-184, an alkylating agent engineered to inflict DNA damage upon cancer cells that either overexpress specific biomarkers or exhibit mutations within their DNA repair pathways. Beyond these, Lantern Pharma maintains an antibody-drug conjugate (ADC) program for diverse cancer treatments. Central to their operations is the RADR artificial intelligence platform, which synergizes molecular data through advanced big data analytics and machine learning capabilities. Established in 2013, the company operates from its headquarters in Dallas, Texas.
收盘时
US$0.737
−US$0.0757 · -9.31%
盘后
US$0.7264
−US$0.0106 · -1.44%
10月12日 19:30 ET
盘中时间采用ET。市场数据可能有所延迟。
Lantern Pharma Inc. is a clinical-stage biotechnology firm dedicated to revolutionizing drug development through the strategic application of artificial intelligence, machine learning, and comprehensive genomic data analysis. Their primary drug candidate, LP-100, is currently undergoing Phase II clinical trials, targeting metastatic, castration-resistant prostate cancer. The company is also advancing LP-300 as a potential combination therapy for non-small cell lung cancer adenocarcinoma, specifically in individuals who are non-smokers or have never smoked. Furthermore, their preclinical pipeline includes LP-184, an alkylating agent engineered to inflict DNA damage upon cancer cells that either overexpress specific biomarkers or exhibit mutations within their DNA repair pathways. Beyond these, Lantern Pharma maintains an antibody-drug conjugate (ADC) program for diverse cancer treatments. Central to their operations is the RADR artificial intelligence platform, which synergizes molecular data through advanced big data analytics and machine learning capabilities. Established in 2013, the company operates from its headquarters in Dallas, Texas.
日内区间
当前US$0.737
52周区间
当前US$0.737
盘中时间采用ET。市场数据可能有所延迟。
Lantern Pharma Inc. is a clinical-stage biotechnology firm dedicated to revolutionizing drug development through the strategic application of artificial intelligence, machine learning, and comprehensive genomic data analysis. Their primary drug candidate, LP-100, is currently undergoing Phase II clinical trials, targeting metastatic, castration-resistant prostate cancer. The company is also advancing LP-300 as a potential combination therapy for non-small cell lung cancer adenocarcinoma, specifically in individuals who are non-smokers or have never smoked. Furthermore, their preclinical pipeline includes LP-184, an alkylating agent engineered to inflict DNA damage upon cancer cells that either overexpress specific biomarkers or exhibit mutations within their DNA repair pathways. Beyond these, Lantern Pharma maintains an antibody-drug conjugate (ADC) program for diverse cancer treatments. Central to their operations is the RADR artificial intelligence platform, which synergizes molecular data through advanced big data analytics and machine learning capabilities. Established in 2013, the company operates from its headquarters in Dallas, Texas.
日内区间
当前US$0.737
52周区间
当前US$0.737
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 销货成本 | — | — | 17.48万 USD | — | — |
| 毛利 | — | — | −17.48万 USD | — | — |
| 研究与开发 | 1151.41万 USD | 1612.57万 USD | 1189.43万 USD | 86.03亿 USD | 757.06万 USD |
| 销售、一般及管理费用 | 646.44万 USD | 609.07万 USD | 598.33万 USD | 58.3亿 USD | 502.09万 USD |
| 营业费用 | 1797.85万 USD | 2221.64万 USD | 1770.27万 USD | 144.33亿 USD | 1259.15万 USD |
| 利息收入 | 43.79万 USD | 74.24万 USD | 76.54万 USD | 2.04亿 USD | 6.79万 USD |
| 折旧和摊销 | 1.73万 USD | 1.73万 USD | 1.46万 USD | 1.01万 USD | 6761 USD |
| 营业利润 | −1797.85万 USD | −2221.64万 USD | −1787.76万 USD | −144.33亿 USD | −1259.15万 USD |
| 净利润 | −1711.94万 USD | −2078.12万 USD | −1596.15万 USD | −142.6亿 USD | −1236.3万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI68.69万0.00%2.3万亿 USD0.03%US$381.57-0.10%
Vanguard Extended Market ETFVXF16.63万0.00%954亿 USD0.05%US$233.52-0.63%
Horizon Kinetics Medical ETFMEDX1.85万0.11%1656.51万 USD0.85%US$35.2544+1.60%
Dimensional - US Sustainability Core 1 ETFDFSU1563.630.00%23.92亿 USD0.15%US$48.13+0.04%
Dimensional - US Core Equity 2 ETFDFAC522.570.00%885.96亿 USD0.21%US$45.31-0.04%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFHorizon Kinetics Medical ETFMEDXDimensional - US Sustainability Core 1 ETFDFSUDimensional - US Core Equity 2 ETFDFACAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
